Nucleic Acid Therapeutics Market (Product Type: RNA interference (RNAi) and Short Interfering RNAs, Antisense Oligonucleotides (ASOs), and Others; and Application: Autoimmune Disorders, Infectious Diseases, Genetic Disorders, Cancer, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034
Nucleic Acid Therapeutics Market – Scope of Report
TMR’s report on the global nucleic acid therapeutics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global nucleic acid therapeutics market for the period 2018–2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global nucleic acid therapeutics market from 2024 to 2034.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the nucleic acid therapeutics market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global nucleic acid therapeutics market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global nucleic acid therapeutics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global nucleic acid therapeutics market.
The report delves into the competitive landscape of the global nucleic acid therapeutics market. Key players operating in the global nucleic acid therapeutics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global nucleic acid therapeutics market profiled in this report.
Key Questions Answered in Global nucleic acid therapeutics Market Report
- What is the sales/revenue generated by nucleic acid therapeutics across all regions during the forecast period?
- What are the opportunities in the global nucleic acid therapeutics market?
- What are the major drivers, restraints, opportunities, and threats in the market?
- Which regional market is set to expand at the fastest CAGR during the forecast period?
- Which segment is expected to generate the highest revenue globally in 2034?
- Which segment is projected to expand at the highest CAGR during the forecast period?
- What are the market positions of different companies operating in the global market?
The comprehensive report on the global nucleic acid therapeutics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global nucleic acid therapeutics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global nucleic acid therapeutics market.
- 1. Preface
- 1.1. Market Definition and Scope
- 1.2. Market Segmentation
- 1.3. Key Research Objectives
- 1.4. Research Highlights
- 2. Assumptions and Research Methodology
- 3. Executive Summary: Global Nucleic Acid Therapeutics Market
- 4. Market Overview
- 4.1. Introduction
- 4.1.1. Segment Definition
- 4.2. Overview
- 4.3. Market Dynamics
- 4.3.1. Drivers
- 4.3.2. Restraints
- 4.3.3. Opportunities
- 4.4. Global Nucleic Acid Therapeutics Market Analysis and Forecasts, 2020-2034
- 4.4.1. Market Revenue Projections (US$ Mn)
- 5. Key Insights
- 5.1. Pipeline Analysis
- 5.2. Regulatory Scenario by Countries
- 5.3. Technological Advancement
- 5.4. Reimbursement Scenario
- 5.5. PESTEL Analysis
- 5.6. Porter’s Five Force Analysis
- 5.7. Impact Analysis on Market
- 5.8. Investment Scenario
- 5.9. Unmet Needs in Current Treatment Landscape
- 6. Global Nucleic Acid Therapeutics Market Analysis and Forecasts, By Product
- 6.1. Introduction & Definition
- 6.2. Key Findings / Developments
- 6.3. Market Value Forecast By Product, 2020-2034
- 6.3.1. Anti-Sense Oligonucleotides (ASO)
- 6.3.2. RNA Interference (RNAi)
- 6.3.3. RNA Aptamers
- 6.4. Market Attractiveness By Product
- 7. Global Nucleic Acid Therapeutics Market Analysis and Forecasts, By Indication
- 7.1. Introduction & Definition
- 7.2. Key Findings / Developments
- 7.3. Market Value Forecast By Indication, 2020-2034
- 7.3.1. Autoimmune Disorders
- 7.3.2. Infectious Diseases
- 7.3.3. Genetic Disorders
- 7.3.4. Cancer
- 7.3.5. Others
- 7.4. Market Attractiveness By Indication
- 8. Global Nucleic Acid Therapeutics Market Analysis and Forecasts, By End-user
- 8.1. Introduction & Definition
- 8.2. Key Findings / Developments
- 8.3. Market Value Forecast By End-user, 2020-2034
- 8.3.1. Hospitals
- 8.3.2. Physicians’ Offices
- 8.3.3. Others
- 8.4. Market Attractiveness By End-user
- 9. Global Nucleic Acid Therapeutics Market Analysis and Forecasts, By Region
- 9.1. Key Findings
- 9.2. Market Value Forecast By Region
- 9.2.1. North America
- 9.2.2. Europe
- 9.2.3. Asia Pacific
- 9.2.4. Latin America
- 9.2.5. Middle East & Africa
- 9.3. Market Attractiveness By Country/Region
- 10. North America Nucleic Acid Therapeutics Market Analysis and Forecast
- 10.1. Introduction
- 10.1.1. Key Findings
- 10.2. Market Value Forecast By Product, 2020-2034
- 10.2.1. Anti-Sense Oligonucleotides (ASO)
- 10.2.2. RNA Interference (RNAi)
- 10.2.3. RNA Aptamers
- 10.3. Market Value Forecast By Indication, 2020-2034
- 10.3.1. Autoimmune Disorders
- 10.3.2. Infectious Diseases
- 10.3.3. Genetic Disorders
- 10.3.4. Cancer
- 10.3.5. Others
- 10.4. Market Value Forecast By End-user, 2020-2034
- 10.4.1. Hospitals
- 10.4.2. Physicians’ Offices
- 10.4.3. Others
- 10.5. Market Value Forecast By Country, 2020-2034
- 10.5.1. U.S.
- 10.5.2. Canada
- 10.6. Market Attractiveness Analysis
- 10.6.1. By Product
- 10.6.2. By Indication
- 10.6.3. By End-user
- 10.6.4. By Country
- 11. Europe Nucleic Acid Therapeutics Market Analysis and Forecast
- 11.1. Introduction
- 11.1.1. Key Findings
- 11.2. Market Value Forecast By Product, 2020-2034
- 11.2.1. Anti-Sense Oligonucleotides (ASO)
- 11.2.2. RNA Interference (RNAi)
- 11.2.3. RNA Aptamers
- 11.3. Market Value Forecast By Indication, 2020-2034
- 11.3.1. Autoimmune Disorders
- 11.3.2. Infectious Diseases
- 11.3.3. Genetic Disorders
- 11.3.4. Cancer
- 11.3.5. Others
- 11.4. Market Value Forecast By End-user, 2020-2034
- 11.4.1. Hospitals
- 11.4.2. Physicians’ Offices
- 11.4.3. Others
- 11.5. Market Value Forecast By Country/Sub-region, 2020-2034
- 11.5.1. Germany
- 11.5.2. U.K.
- 11.5.3. France
- 11.5.4. Italy
- 11.5.5. Spain
- 11.5.6. Rest of Europe
- 11.6. Market Attractiveness Analysis
- 11.6.1. By Product
- 11.6.2. By Indication
- 11.6.3. By End-user
- 11.6.4. By Country/Sub-region
- 12. Asia Pacific Nucleic Acid Therapeutics Market Analysis and Forecast
- 12.1. Introduction
- 12.1.1. Key Findings
- 12.2. Market Value Forecast By Product, 2020-2034
- 12.2.1. Anti-Sense Oligonucleotides (ASO)
- 12.2.2. RNA Interference (RNAi)
- 12.2.3. RNA Aptamers
- 12.3. Market Value Forecast By Indication, 2020-2034
- 12.3.1. Autoimmune Disorders
- 12.3.2. Infectious Diseases
- 12.3.3. Genetic Disorders
- 12.3.4. Cancer
- 12.3.5. Others
- 12.4. Market Value Forecast By End-user, 2020-2034
- 12.4.1. Hospitals
- 12.4.2. Physicians’ Offices
- 12.4.3. Others
- 12.5. Market Value Forecast By Country/Sub-region, 2020-2034
- 12.5.1. China
- 12.5.2. India
- 12.5.3. Japan
- 12.5.4. Australia & New Zealand
- 12.5.5. Rest of Asia Pacific
- 12.6. Market Attractiveness Analysis
- 12.6.1. By Product
- 12.6.2. By Indication
- 12.6.3. By End-user
- 12.6.4. By Country/Sub-region
- 13. Latin America Nucleic Acid Therapeutics Market Analysis and Forecast
- 13.1. Introduction
- 13.1.1. Key Findings
- 13.2. Market Value Forecast By Product, 2020-2034
- 13.2.1. Anti-Sense Oligonucleotides (ASO)
- 13.2.2. RNA Interference (RNAi)
- 13.2.3. RNA Aptamers
- 13.3. Market Value Forecast By Indication, 2020-2034
- 13.3.1. Autoimmune Disorders
- 13.3.2. Infectious Diseases
- 13.3.3. Genetic Disorders
- 13.3.4. Cancer
- 13.3.5. Others
- 13.4. Market Value Forecast By End-user, 2020-2034
- 13.4.1. Hospitals
- 13.4.2. Physicians’ Offices
- 13.4.3. Others
- 13.5. Market Value Forecast By Country/Sub-region, 2020-2034
- 13.5.1. Brazil
- 13.5.2. Mexico
- 13.5.3. Rest of Latin America
- 13.6. Market Attractiveness Analysis
- 13.6.1. By Product
- 13.6.2. By Indication
- 13.6.3. By End-user
- 13.6.4. By Country/Sub-region
- 14. Middle East & Africa Nucleic Acid Therapeutics Market Analysis and Forecast
- 14.1. Introduction
- 14.1.1. Key Findings
- 14.2. Market Value Forecast By Product, 2020-2034
- 14.2.1. Anti-Sense Oligonucleotides (ASO)
- 14.2.2. RNA Interference (RNAi)
- 14.2.3. RNA Aptamers
- 14.3. Market Value Forecast By Indication, 2020-2034
- 14.3.1. Autoimmune Disorders
- 14.3.2. Infectious Diseases
- 14.3.3. Genetic Disorders
- 14.3.4. Cancer
- 14.3.5. Others
- 14.4. Market Value Forecast By End-user, 2020-2034
- 14.4.1. Hospitals
- 14.4.2. Physicians’ Offices
- 14.4.3. Others
- 14.5. Market Value Forecast By Country/Sub-region, 2020-2034
- 14.5.1. GCC
- 14.5.2. South Africa
- 14.5.3. Rest of Middle East & Africa
- 14.6. Market Attractiveness Analysis
- 14.6.1. By Product
- 14.6.2. By Indication
- 14.6.3. By End-user
- 14.6.4. By Country/Sub-region
- 15. Competition Landscape
- 15.1. Market Player - Competition Matrix (By Tier and Size of companies)
- 15.2. Market Share Analysis By Company (2023)
- 15.3. Company Profiles
- 15.3.1. Alynylam Pharmaceutials, Inc.
- 15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
- 15.3.1.2. Product Portfolio
- 15.3.1.3. Financial Overview
- 15.3.1.4. SWOT Analysis
- 15.3.1.5. Strategic Overview
- 15.3.2. BioNTech
- 15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
- 15.3.2.2. Product Portfolio
- 15.3.2.3. Financial Overview
- 15.3.2.4. SWOT Analysis
- 15.3.2.5. Strategic Overview
- 15.3.3. Ionis Pharmaceuticals, Inc.
- 15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
- 15.3.3.2. Product Portfolio
- 15.3.3.3. Financial Overview
- 15.3.3.4. SWOT Analysis
- 15.3.3.5. Strategic Overview
- 15.3.4. Moderna
- 15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
- 15.3.4.2. Product Portfolio
- 15.3.4.3. Financial Overview
- 15.3.4.4. SWOT Analysis
- 15.3.4.5. Strategic Overview
- 15.3.5. Nippon Shinyaku
- 15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
- 15.3.5.2. Product Portfolio
- 15.3.5.3. Financial Overview
- 15.3.5.4. SWOT Analysis
- 15.3.5.5. Strategic Overview
- 15.3.6. Novartis
- 15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
- 15.3.6.2. Product Portfolio
- 15.3.6.3. Financial Overview
- 15.3.6.4. SWOT Analysis
- 15.3.6.5. Strategic Overview
- 15.3.7. Pfizer
- 15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
- 15.3.7.2. Product Portfolio
- 15.3.7.3. Financial Overview
- 15.3.7.4. SWOT Analysis
- 15.3.7.5. Strategic Overview
- 15.3.8. Sarepta Therapeutics
- 15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
- 15.3.8.2. Product Portfolio
- 15.3.8.3. Financial Overview
- 15.3.8.4. SWOT Analysis
- 15.3.8.5. Strategic Overview
- 15.3.9. Biogen Inc.
- 15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
- 15.3.9.2. Product Portfolio
- 15.3.9.3. Financial Overview
- 15.3.9.4. SWOT Analysis
- 15.3.9.5. Strategic Overview
- 15.3.10. Genzyme Sanofi
- 15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
- 15.3.10.2. Product Portfolio
- 15.3.10.3. Financial Overview
- 15.3.10.4. SWOT Analysis
- 15.3.10.5. Strategic Overview
- 15.3.11. Percheron Therapeutics Ltd.
- 15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
- 15.3.11.2. Product Portfolio
- 15.3.11.3. Financial Overview
- 15.3.11.4. SWOT Analysis
- 15.3.11.5. Strategic Overview
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook